Home R&D Pipeline

Pipeline

RNAi is a Nobel Prize-winning technology that utilizes the power of nature's biological mechanisms to silence targeted genes.

Home R&D Pipeline

Pipeline

RNAi is a Nobel Prize-winning technology that utilizes the power of nature's biological mechanisms to silence targeted genes.

As a platform company, Argo Biopharma has a rich portfolio of product pipelines covering a wide range of indications, including cardiovascular diseases, rare diseases, CNS disorders, viral hepatitis, metabolic conditions, and more.

Therapy area
  • Target
  • Indications
  • Discovery
  • PCC
  • IND enabling
  • Phase I
  • Phase II
  • Phase III
  • Partner
Cardiovascular
disease
  • BW-01
  • Cardiovascular disease
  • BW-02
  • Cardiovascular disease
  • ex-China license

  • BW-05
  • Cardiovascular disease
  • BW-07
  • Cardiovascular disease
  • BW-15
  • Cardiovascular disease
  • BW-23
  • Cardiovascular disease
  • BW-24
  • Cardiovascular disease
  • BW-30
  • Cardiovascular disease
  • BW-32
  • Cardiovascular disease
  • BW-34
  • Cardiovascular disease
Rare
disease
  • PKK
  • HAE
  • C3
  • PNH, C3G, IgAN
  • C5
  • IgAN,MG,PNH, aHUS
  • CFB
  • MG,PNH, lgAN
  • TMPRSS6
  • Hematology disorders
  • TTR
  • ATTR-CM,stargardt disease
Virus
infection
  • HBV
  • Hepatitis B
  • BW-08
  • Undisclosed
Metabolic
disease
  • INHBE
  • Obesity, Metabolic syndrome
  • PNPLA3
  • NASH
  • HSD17B13
  • NASH
  • CIDEB
  • NASH
CNS
disease
  • BWS-2
  • Huntington's Disease
  • BWS-3
  • Alzheimer's Disease
  • BWS-4
  • Alzheimer's Disease
  • BWS-7
  • Parkinson's Disease
  • BWS-8
  • Parkinson's Disease
  • BWS-9
  • Pain

Copyright © 2023 Argo Biopharma. All rights reserved.

Privacy Policy | Site Map

为了更好的呈现效果,移动端请竖屏浏览